Radioiodine Therapy in Advanced Differentiated Thyroid Cancer: Resistance and Overcoming Strategy

AbbreviationAD

Absorbed Radiation Dose

APL

Acute Promyelocytic Leukemia

ATRA

All-Trans Retinoic Acid

CAF

Cancer-Associated Fibroblasts

CREB

cAMP-Responsive Element-Binding Protein

DTC

Differentiated Thyroid Cancer

EMA

European Medicines Agency

EVs

Extracellular Vesicles

FDA

Food and Drug Administration

GIST

Gastrointestinal Stromal Tumor

HCC

HÜrthle Cell Carcinoma

MKIs

Multiple Kinase Inhibitors

NGS

Next-Generation Sequencing

NIS

Sodium Iodide Symporter

NMPA

National Medical Products Administration

ORR

Objective Response Rate

PDGFR

Platelet Derived Growth Factor Receptor

PDTC

Poorly Differentiated Thyroid Carcinoma

PFS

Progression Free Survival

PMAA-AuNPs

Poly (Methacrylic Acid)-Grafted Gold Nanoparticles

PNET

Pancreatic Neuroendocrine Tumor

PSMA

Prostate-Specific Membrane Antigen

RAIR-DTC

RAI Refractory Differentiated Thyroid Cancer

rhTSH

Recombinant Human TSH

SH

Sinomenine Hydrochloride

SSRT

Somatostatin Receptors

TCGA

The Cancer Genome Atlas

THW

Thyroid Hormone Withdrawal

TKIs

Tyrosine Kinase Inhibitors

TKR

TK Transmembrane Receptor

TME

Tumor Microenvironment

TSH

Thyroid Stimulating Hormone

VCP

Valosin Containing Protein

VEGFR

Vascular Endothelial Growth Factor Receptor

Keywords

Advanced Differentiated Thyroid Cancer

Radioiodine (RAI) resistance

Molecular Mechanisms

Sodium Iodide Symporter (NIS)

Tyrosine kinase inhibitors (TKIs)

© 2023 Published by Elsevier Ltd.

留言 (0)

沒有登入
gif